WINTON GROUP Ltd Boosts Stake in Editas Medicine, Inc. (NASDAQ:EDIT)

WINTON GROUP Ltd lifted its holdings in Editas Medicine, Inc. (NASDAQ:EDITGet Rating) by 27.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,402 shares of the company’s stock after buying an additional 4,766 shares during the quarter. WINTON GROUP Ltd’s holdings in Editas Medicine were worth $265,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of EDIT. DekaBank Deutsche Girozentrale boosted its stake in shares of Editas Medicine by 9.8% in the first quarter. DekaBank Deutsche Girozentrale now owns 22,400 shares of the company’s stock valued at $437,000 after buying an additional 2,000 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Editas Medicine in the first quarter valued at approximately $721,000. Envestnet Asset Management Inc. boosted its stake in shares of Editas Medicine by 35.6% in the first quarter. Envestnet Asset Management Inc. now owns 24,061 shares of the company’s stock valued at $458,000 after buying an additional 6,314 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Editas Medicine by 56.8% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 6,778 shares of the company’s stock valued at $129,000 after buying an additional 2,455 shares in the last quarter. Finally, HCR Wealth Advisors raised its holdings in Editas Medicine by 6.3% during the first quarter. HCR Wealth Advisors now owns 21,000 shares of the company’s stock worth $399,000 after purchasing an additional 1,250 shares during the last quarter. 68.77% of the stock is currently owned by hedge funds and other institutional investors.

Editas Medicine Trading Down 0.5 %

Editas Medicine stock opened at $10.95 on Monday. The firm has a market capitalization of $752.95 million, a P/E ratio of -3.72 and a beta of 1.96. The stock has a fifty day moving average price of $12.57 and a 200 day moving average price of $13.53. Editas Medicine, Inc. has a 52 week low of $9.59 and a 52 week high of $36.53.

Editas Medicine (NASDAQ:EDITGet Rating) last released its earnings results on Wednesday, November 2nd. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.06. Editas Medicine had a negative return on equity of 41.33% and a negative net margin of 784.32%. The firm had revenue of $0.04 million during the quarter, compared to analyst estimates of $5.86 million. As a group, equities analysts predict that Editas Medicine, Inc. will post -3.23 EPS for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on EDIT shares. Royal Bank of Canada reduced their price objective on Editas Medicine from $32.00 to $14.00 and set a “sector perform” rating for the company in a report on Friday. Credit Suisse Group cut Editas Medicine from an “outperform” rating to a “neutral” rating and reduced their price objective for the stock from $25.00 to $13.00 in a report on Thursday. Oppenheimer cut Editas Medicine from an “outperform” rating to a “market perform” rating and reduced their price objective for the stock from $28.00 to $12.00 in a report on Thursday. Barclays boosted their price target on Editas Medicine from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Thursday, August 4th. Finally, StockNews.com assumed coverage on Editas Medicine in a report on Wednesday, October 12th. They issued a “sell” rating for the company. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Editas Medicine presently has a consensus rating of “Hold” and a consensus target price of $16.42.

Editas Medicine Company Profile

(Get Rating)

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness.

Featured Stories

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDITGet Rating).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.